Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04318080
Title Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors BeiGene
Indications

Hodgkin's lymphoma

Therapies

Tislelizumab

Age Groups: adult | senior
Covered Countries USA | FRA | BEL


No variant requirements are available.